Does in vitro susceptibility predict clinical outcome in bacterial keratitis?

American Journal of Ophthalmology
Aiyin ChenNisha R Acharya

Abstract

To determine whether clinical outcomes in bacterial keratitis are associated with antibiotic susceptibility. Retrospective, ancillary study using data and samples from a completed randomized clinical trial. Forty-two patients were enrolled with culture-confirmed bacterial keratitis at Aravind Eye Hospital in South India. All patients received topical moxifloxacin and were randomized to receive either topical prednisolone phosphate or placebo. Outcomes included time to epithelialization, best spectacle-corrected visual acuity (BSCVA), and infiltrate/scar size at three months. Bacterial isolates were cultured, and minimum inhibitory concentration (MIC) to moxifloxacin was measured using Etests. Multiple linear regression was used to assess the effect of MIC on outcome, adjusting for enrollment characteristics. MIC was associated with three-month infiltrate/scar size: each two-fold increase in MIC was associated with a 0.33-mm average diameter increase in scar size (P=.01). MIC was not associated with three-month BSCVA (P=.71) or time to epithelialization (P=.35). MIC was associated with infiltrate/scar size in bacterial keratitis. An ongoing larger, multicenter trial should provide further information on whether this association ...Continue Reading

References

Jan 1, 1990·The Journal of Antimicrobial Chemotherapy·V Lorian, L Burns
Dec 1, 1993·Archives of Ophthalmology·J C ErieD J Ballard
Dec 1, 1996·Ophthalmic Epidemiology·C A GonzalesG Smolin
Aug 1, 1997·The British Journal of Ophthalmology·J P Whitcher, M Srinivasan
Nov 1, 2005·Survey of Ophthalmology·Barry A Schlech, Eduardo Alfonso

❮ Previous
Next ❯

Citations

Oct 12, 2011·Archives of Ophthalmology·Muthiah SrinivasanUNKNOWN Steroids for Corneal Ulcers Trial Group
Oct 12, 2011·Archives of Ophthalmology·Muthiah SrinivasanUNKNOWN Steroids for Corneal Ulcers Trial Group
Apr 13, 2011·Archives of Ophthalmology·Robert E FintelmannNisha R Acharya
Jan 12, 2013·JAMA Ophthalmology·Kathryn J RayThomas M Lietman
Mar 30, 2011·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Stephen KayeTimothy Neal
Sep 28, 2013·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Fırat Zafer MengeloğluHayrettin Akdeniz
Mar 27, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Prajna LalithaThomas M Lietman
Sep 11, 2012·American Journal of Ophthalmology·Prajna LalithaNisha R Acharya
Oct 21, 2014·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Sertan GoktasAbdulkadir Bukus
Nov 20, 2014·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Barry A SchechterWilliam Trattler
Sep 20, 2012·Journal of Ophthalmology·Raymond L M WongJimmy S M Lai
Dec 14, 2019·Eye & Contact Lens·Mark D P Willcox
Jun 3, 2021·Clinical Microbiology Reviews·Sixto M LealPeter H Gilligan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.